M

MacroGenics
D

MGNX

3.19500
USD
0.01
(0.16%)
Market Open
Volume
3,208
EPS
-1
Div Yield
-
P/E
-2
Market Cap
200,529,216
OverviewSignalsIdeasNews
Related Instruments
    A
    ARRY
    0.16000
    (2.85%)
    5.78000 USD
    B
    BLUE
    -0.66000
    (-7.77%)
    7.83000 USD
    C
    CRSP
    -0.480
    (-1.18%)
    40.240 USD
    E
    EDIT
    -0.05500
    (-4.17%)
    1.26500 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    N
    NKTR
    -0.04880
    (-5.30%)
    0.87120 USD
    S
    SGMO
    0.05500
    (2.21%)
    2.54500 USD
    X
    XNCR
    0.220
    (0.91%)
    24.380 USD
    More
News

Title: MacroGenics

Sector: Healthcare
Industry: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).